☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Arrowhead
Arrowhead Presents New P-II (ARCHES-2) Findings for Zodasiran at AHA 2023
November 14, 2023
Arrowhead Published New Findings from 2 P-II (SHASTA-2 & MUIR) studies for Plozasiran at AHA 2023
November 14, 2023
Arrowhead and Janssen Entered into a Licensing Agreement with GSK for JNJ-3989 to Treat Chronic Hepatitis B
November 1, 2023
Arrowhead Reports the First Patient Dosing of Fazirsiran in the P-III Trial (REDWOOD) for Alpha-1 Antitrypsin Deficiency Associate...
April 5, 2023
Arrowhead Gains Full Rights to ARO-PNPLA3 for Patients with Non-Alcoholic Steatohepatitis
February 16, 2023
Arrowhead and Takeda Report P-II Study (SEQUOIA) of Fazirsiran for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
January 10, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.